Skip to content
Calculator
Evidence: LowPeptideResearch ChemicalNatural tetrapeptide (Ac-SDKP)Not approved · 1995 trial negativeAntifibrotic in animals

Goralatide

The stem-cell brake hidden inside thymosin beta-4

Goralatide is the international name for Ac-SDKP, a four-amino-acid peptide the body cuts from thymosin beta-4 and that the enzyme ACE breaks down. It keeps blood stem cells from dividing, so it was tested in the 1990s as a way to shield bone marrow from chemotherapy; a randomized trial found no benefit. Animal studies since cast it as an antifibrotic.

Used in human trials: 12.5 or 62.5 µg/kg, Daily, Not stated in the abstract (Trial: myeloprotection with carboplatin and fluorouracil) Details ↓

Overview

What is it?

Ac-SDKP was found as a natural inhibitor of blood stem cell division: it stops stem cells and early progenitors from entering the S-phase, when DNA is copied. Since chemotherapy kills dividing cells, keeping marrow stem cells resting might spare them. In the lab it slowed normal human marrow progenitors but not leukaemia cells, and in mice it reduced deaths from doxorubicin.

The human test did not bear this out. In a French double-blind trial, 84 patients with head and neck or oesophageal cancer receiving carboplatin and fluorouracil were given goralatide (12.5 or 62.5 micrograms per kg a day for four days) or placebo. Across 221 chemotherapy cycles, there was no difference in white cell, granulocyte or platelet nadirs or in the length of blood toxicity; anaemia and lymphopenia were more frequent with goralatide. It was well tolerated.

A second story then took over. ACE, the enzyme that blood pressure drugs such as captopril block, breaks Ac-SDKP down, so those drugs raise its levels several-fold in people. In hypertensive rats, Ac-SDKP at matching levels reduced heart inflammation and collagen as much as captopril did, without lowering blood pressure, suggesting the peptide carries part of the drugs' antifibrotic effect.

Rodent studies have since reported benefits in radiation heart damage and in kidney, liver and lung fibrosis. Reviews describe a thymosin beta-4 to Ac-SDKP axis in repair, the link to TB-500, which is based on another part of that protein.

The ACE link has one practical human use. Since ACE inhibitors raise Ac-SDKP, a urine test detected whether patients were taking their ACE inhibitor with 92.2% sensitivity and 100% specificity. In diabetic mice, the kidney protection from the ACE inhibitor imidapril depended on Ac-SDKP, and an angiotensin receptor blocker, which does not raise it, did not give the same effect.

The animal record keeps widening. A meta-analysis of 18 studies found less lung fibrosis with Ac-SDKP; rodent studies report benefit in colitis, spinal cord injury and a Parkinson's model; and a longer-acting isomer reduced lung fibrosis in rodents. No antifibrotic human trial appears in what we read, and goralatide is approved nowhere.

84
Patients in the only human trial
no marrow protection · PMID 8535033
92.2%
Sensitivity of a urine adherence test
ACE inhibitors raise Ac-SDKP · PMID 34508023
18
Animal lung-fibrosis studies pooled
consistent reductions · PMID 37248179
Science

Mechanism of Action

Goralatide (Ac-SDKP) is a natural tetrapeptide that holds blood stem cells out of division and is broken down by ACE; it is now studied mainly as an antifibrotic signal.

🩸

Stem-cell quiescence

It keeps marrow stem cells from entering S-phase, the idea behind chemotherapy protection that failed in its human trial.

💊

Raised by ACE inhibitors

ACE degrades it, so ACE inhibitors raise its levels; its urine level can show whether patients take them.

🧵

Antifibrotic

In rodents it reduced fibrosis in heart, kidney and lung, partly through endothelial FGFR signalling.

Evidence

Published Research

Studies of goralatide (Ac-SDKP), from their PubMed abstracts.

Human1995

Randomized myeloprotection trial

In 84 patients on carboplatin and fluorouracil, goralatide (12.5 or 62.5 micrograms/kg/day, days 1-4) did not change blood count nadirs or the duration of blood toxicity versus placebo; anaemia and lymphopenia were more frequent with it.

PMID: 8535033
Human1996

Captopril raises Ac-SDKP

In 8 healthy volunteers in a double-blind crossover study, one 50 mg dose of captopril blocked 90-99% of Ac-SDKP breakdown and raised plasma levels a long-lasting 5.5-fold (range 4-8.5).

PMID: 8609242
Human1999

Clearance during ACE inhibition

Captopril raised plasma AcSDKP 4- to 4.8-fold in healthy subjects; in chronic renal failure, plasma levels were 22 times higher with ACE inhibitors than without (95% CI 15 to 33).

PMID: 10082503
Human2022

A urine test for ACE-inhibitor adherence

Because ACE inhibitors raise Ac-SDKP, its urine level tracked perindoprilat in volunteers and the drug metabolites in patients, detecting adherence with 92.2% sensitivity and 100% specificity.

PMID: 34508023
Animal2004

Heart fibrosis in hypertensive rats

At 400 micrograms/kg/day, Ac-SDKP raised plasma levels to those seen with captopril and, like captopril, reduced angiotensin II-induced cell proliferation, macrophage infiltration and collagen in the left ventricle without lowering blood pressure.

PMID: 15076166
Animal2018

Radiation damage to the heart

In rats given cardiac irradiation, 18 weeks of Ac-SDKP strongly inhibited loss of contractile function, macrophage infiltration, fibrosis and galectin-3 release.

PMID: 30354563
Animal1998

Doxorubicin toxicity in mice

Ac-SDKP for 3 days starting 48 hours before doxorubicin reduced mouse deaths and protected long-term reconstituting stem cells and progenitors; G-CSF afterwards improved recovery.

PMID: 9427696
In Vitro1992

Normal versus leukaemic cells

AcSDKP inhibited normal human marrow progenitors at nanomolar concentrations but did not change proliferation of HL-60, AML or CML cells at any dose.

PMID: 1544396
Review2022

The thymosin beta-4 axis in fibrosis

Prolyl oligopeptidase cleaves thymosin beta-4 to release Ac-SDKP, and this axis is reviewed as protective against liver, kidney, heart and lung fibrosis.

PMID: 36362069
Review2020

An antifibrotic peptide in diabetic kidney disease

A review summarises Ac-SDKP's shift from stem-cell regulator to antifibrotic peptide, including evidence that it targets endothelial-mesenchymal transition through FGFR signalling.

PMID: 31997585
Review2023

Lung fibrosis meta-analysis (animals)

Pooling 18 papers with 428 animal models of pulmonary fibrosis, Ac-SDKP lowered α-smooth muscle actin, collagen types I and III, TGF-β and nodule area against controls.

PMID: 37248179
Animal2020

Why ACE inhibitors protect diabetic kidneys

In diabetic mice, the antifibrotic effect of the ACE inhibitor imidapril depended on Ac-SDKP and its restoration of mitochondrial fat oxidation; blocking Ac-SDKP synthesis accelerated fibrosis, and an angiotensin receptor blocker did not raise it.

PMID: 32352559
Animal2026

Timing in kidney fibrosis

In a mouse kidney injury model, early Ac-SDKP reduced fibrosis, preserved capillaries and improved kidney function, while later treatment was less effective; in injured tubular cells it had an unexpected opposing effect.

PMID: 42726771
Animal2020

Colitis

Mice with lower Ac-SDKP had worse chemically induced colitis, and infusing Ac-SDKP reduced intestinal inflammation.

PMID: 32435194
Animal2025

Parkinson's model

In a rat model of Parkinson's disease, Ac-SDKP improved motor and memory performance and reduced oxidative stress, ER stress and neuroinflammation.

PMID: 40544680
Animal2022

Spinal cord injury

After spinal cord injury in rats, Ac-SDKP improved locomotor recovery, reduced motor neuron loss and TNF-α, and raised a marker of repair-type macrophages.

PMID: 35101843
Animal2020

A longer-acting isomer

A long-acting isomer of Ac-SDKP reduced lung fibrosis in rodents by inhibiting SRPK1-driven PI3K/AKT and Smad2 signalling.

PMID: 33135306
Dosing

Dosing Data

Not approved anywhere. Its one randomised human trial gave it for four days around chemotherapy.

Research peptide; the only human trial found no benefit.
ProtocolDoseFrequencyDurationRoute
Trial: myeloprotection with carboplatin and fluorouracil Human studyPMID 853503312.5 or 62.5 µg/kgDailyDays 1 to 4Not stated in the abstract

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

A research dose only
The single human trial dosed by weight in micrograms per kilogram; there is no clinical dose.
Open Calculator →
For Buyers

What a Buyer Needs to Know

What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.

What is sold

Unknown: we hold no label and no published test that says what forms or vial sizes Goralatide is sold in. A vial's own label is a seller's claim, not a source.

Mixing a vial: a worked example

No worked example: none of the doses on this page is a fixed amount in mg or mcg injected under the skin or into a muscle (the routes given are: not stated in the abstract). There is no home-mixing step to show. The reconstitution calculator does the arithmetic for any vial.

Source: the route and amount of each dose row in Dosing Data below.

Storage before and after mixing

Unknown: no label or published stability study on file says how to store Goralatide, before or after mixing. The mixing guide sets out the general rules, with their sources: keep a mixed vial in the fridge, and use it promptly, as the bacteriostatic water label says of any drug dissolved in it. The 28 days often quoted is the limit for an opened multiple-dose vial from a manufacturer, an outer limit set for sterility, not a time a mixed solution has been shown to keep. Nobody has published how long Goralatide stays intact once mixed.

How it is taken

As it was given in human studies: Not stated in the abstract (Daily; Trial: myeloprotection with carboplatin and fluorouracil).

For injection technique, sites and needle disposal, see the mixing guide.

Source: Used in human trials: the route and frequency of each row in Dosing Data below.

What to expect, and when

How long it stays in the body: not established by a measurement cited on this entry.

How long the doses were given: Trial: myeloprotection with carboplatin and fluorouracil: Days 1 to 4.

When effects appear: unknown; no source on this page gives a time to effect for Goralatide. Results reported in the studies are under Published Research.

Source: Used in human trials, the duration of each row in Dosing Data below.

Side effects, and when to stop or get help

From the Side Effects section: Anaemia and lymphopenia were more frequent than with placebo; Clinical and laboratory tolerability were described as excellent. Full list and cautions ↓

When to stop or get help: unknown; no label or trial on file sets rules for stopping Goralatide. Treat a severe or unexpected reaction as a reason to stop and see a doctor.

Source: the Side Effects section below (“From the one randomized human trial”).

Interactions

  • captopril (ACE inhibitor): one 50 mg dose blocked 90-99% of Ac-SDKP breakdown and raised plasma Ac-SDKP about 5.5-fold in healthy volunteers
  • ACE inhibitors in chronic renal failure: plasma Ac-SDKP 22 times higher than in untreated patients (4.1 times with normal kidney function)

Every peptide's record, with its source: the interaction matrix.

Source: human study, PMID 8609242; human study, PMID 10082503.

Checking what you bought

Unknown: no published independent test of Goralatide products is in our lab-results database yet, so how products sold under this name measure up is not known.

To read a certificate of analysis, paste it into the COA decoder; it checks the measured mass against Goralatide's expected mass, 487.5 Da, from this entry's molecular data. Trust & Verification explains what independent testing can and cannot show.

Legal status

US: Research Chemical (Not approved anywhere). Sport: Prohibited (S0 catch-all).

Country by country ↓ · Regulatory tracker

Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.

Safety

Side Effects & Contraindications

Reported Side Effects

From the one randomized human trial.

● Anaemia and lymphopenia were more frequent than with placebo
● Clinical and laboratory tolerability were described as excellent

Contraindications & Cautions

There is no label.

● Not approved for any use; no regulator-reviewed safety information exists
Questions

Frequently Asked Questions

?What is goralatide?

The international name for Ac-SDKP, a natural tetrapeptide (acetyl-Ser-Asp-Lys-Pro) cut from thymosin beta-4. It holds blood stem cells in a resting state and is broken down by ACE.

?Did goralatide protect bone marrow during chemotherapy?

Not in people. It worked in mice, but a 1995 randomized, double-blind trial in 84 patients found no difference from placebo in blood count nadirs, and anaemia and lymphopenia were more common with it.

?Is goralatide related to TB-500?

Yes, through thymosin beta-4. Ac-SDKP is released from that protein by prolyl oligopeptidase, while TB-500 is based on a different part of it. They are separate molecules with separate evidence.

?Does Ac-SDKP explain how ACE inhibitors protect organs?

Partly, in animals: in diabetic mice the ACE inhibitor imidapril's antifibrotic effect depended on Ac-SDKP, and blocking its synthesis accelerated fibrosis.

?Can Ac-SDKP be measured in people?

Yes. Urine Ac-SDKP tracked ACE-inhibitor use closely enough to detect adherence with 92.2% sensitivity and 100% specificity.

Bibliography

References

  1. [other] PubChem CID 65938, Goralatide: formula C20H33N5O9, molecular weight 487.5. Read October 3, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/65938
  2. [fda] FDA. Drugs@FDA (openFDA): no application on record for goralatide. Read October 3, 2026.
  3. [clinical-trial] Cappelaere P, et al. "[Randomized placebo trial of myeloprotection with goralatide in patients with squamous cell carcinoma of the upper respiratory and digestive tracts or esophagus, treated with a carboplatin-fluorouracil combination]." Bull Cancer, 1995;82(9):732-7. PMID: 8535033.
  4. [pubmed] Azizi M, et al. "Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline." J Clin Invest, 1996;97(3):839-44. PMID: 8609242.
  5. [pubmed] Azizi M, et al. "Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans." Hypertension, 1999;33(3):879-86. PMID: 10082503.
  6. [pubmed] Rasoul S, et al. "Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension." J Hypertens, 2004;22(3):593-603. PMID: 15076166.
  7. [pubmed] Sharma UC, et al. "A Small Peptide Ac-SDKP Inhibits Radiation-Induced Cardiomyopathy." Circ Heart Fail, 2018;11(8):e004867. PMID: 30354563.
  8. [pubmed] Massé A, et al. "The tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Goralatide) protects from doxorubicin-induced toxicity: improvement in mice survival and protection of bone marrow stem cells and progenitors." Blood, 1998;91(2):441-9. PMID: 9427696.
  9. [pubmed] Bonnet D, et al. "The tetrapeptide AcSDKP, an inhibitor of the cell-cycle status for normal human hematopoietic progenitors, has no effect on leukemic cells." Exp Hematol, 1992;20(2):251-5. PMID: 1544396.
  10. [pubmed] Wang W, et al. "The Role of Tβ4-POP-Ac-SDKP Axis in Organ Fibrosis." Int J Mol Sci, 2022;23(21). PMID: 36362069.
  11. [pubmed] Kably B, et al. "Urine N-acetyl-Ser-Asp-Lys-Pro measurement as a versatile biomarker to assess adherence to angiotensin-converting enzyme inhibitors." J Hypertens, 2022;40(2):348-355. PMID: 34508023.
  12. [pubmed] Kanasaki K. "N-acetyl-seryl-aspartyl-lysyl-proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: An update and translational aspects." J Diabetes Investig, 2020;11(3):516-526. PMID: 31997585.
  13. [pubmed] Gong HB, et al. "[Meta-analysis of Ac-SDKP inhibition of Pulmonary fibrosis in animal models]." Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, 2023;41(4):262-270. PMID: 37248179.
  14. [pubmed] Srivastava SP, et al. "Metabolic reprogramming by N-acetyl-seryl-aspartyl-lysyl-proline protects against diabetic kidney disease." Br J Pharmacol, 2020;177(16):3691-3711. PMID: 32352559.
  15. [pubmed] Zhu S, et al. "A dual role of AcSDKP in chronic kidney disease: Targeting pericyte-driven fibrosis and vascular repair via VEGF/FGFR1 while eliciting a compensatory FGFR1 upregulation in apoptotic tubular cells." PLoS One, 2026;21(9):e0355409. PMID: 42726771.
  16. [pubmed] Shi Y, et al. "N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Mitigates Experimental Colitis Through Inhibition of Intestinal Mucosal Inflammatory Responses via MEK-ERK Signaling." Front Pharmacol, 2020;11:593. PMID: 32435194.
  17. [pubmed] Kamarehei M, et al. "Neuroprotective effect of Ac-SDKP peptide in SH-SY5Y cells and rat model of Parkinson's disease against 6-OHDA-induced oxidative stress and ER stress." Neuropeptides, 2025;112:102534. PMID: 40544680.
  18. [pubmed] Hashemizadeh S, et al. "Ac-SDKP peptide improves functional recovery following spinal cord injury in a preclinical model." Neuropeptides, 2022;92:102228. PMID: 35101843.
  19. [pubmed] Qiu Y, et al. "A long-acting isomer of Ac-SDKP attenuates pulmonary fibrosis through SRPK1-mediated PI3K/AKT and Smad2 pathway inhibition." IUBMB Life, 2020;72(12):2611-2626. PMID: 33135306.

Sources & Citations

Studies were read from their PubMed abstracts. Read October 7, 2026.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.

Last reviewed: 2026-10-03